Dafna Capital Management LLC Madrigal Pharmaceuticals, Inc. Transaction History

Dafna Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$55.89 - $101.89 $139,725 - $254,725	-2,500 Reduced 44.64%	3,100 $304,000
Q1 2021 May 17, 2021	SELL	$108.54 - $125.2 $108,540 - $125,200	-1,000 Reduced 15.15%	5,600 $655,000
Q2 2020 Aug 14, 2020	SELL	$60.13 - $125.71 $420,910 - $879,970	-7,000 Reduced 51.47%	6,600 $747,000
Q4 2019 Feb 14, 2020	BUY	$84.28 - $118.5 $589,960 - $829,500	7,000 Added 106.06%	13,600 $1.24 Million
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $625,482 - $1.42 Million	6,600 New	6,600 $744,000

298

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.24B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.